



# Analysis of the histamine H<sub>2</sub>-receptor in human monocytes



Kristin Werner, Detlef Neumann, Roland Seifert\*

Institute of Pharmacology, Hannover Medical School, Carl-Neuberg-Straße 1, D-30625 Hannover, Germany

## ARTICLE INFO

### Article history:

Received 27 June 2014

Accepted 25 August 2014

Available online 6 September 2014

### Keywords:

Histamine H<sub>2</sub>-receptor

Functional selectivity

Monocyte

## ABSTRACT

Histamine receptors are G-protein-coupled receptors (GPCRs). Canonically, the histamine H<sub>2</sub>-receptor (H<sub>2</sub>R) couples to G<sub>s</sub>-proteins and activates adenylyl cyclases (ACs) with subsequent adenosine-3',5'-cyclic monophosphate (cAMP) generation. Recently, the classic two-state model describing GPCR activation has been extended to a multiple-state model implying that any ligand stabilizes a ligand-specific receptor conformation, also referred to as functional selectivity. In our present study we pharmacologically characterized the H<sub>2</sub>R in human monocytes. We found dissociations in the effects of histamine (HA) and H<sub>2</sub>R agonists on cAMP accumulation and inhibition of formyl peptide-induced production of reactive oxygen species (ROS). In addition, we excluded participation of protein kinase A (PKA) in HA-induced ROS inhibition. Comparison of the potencies and efficacies of H<sub>2</sub>R agonists in monocytes, neutrophils and eosinophils unmasked cell type-specific pharmacological profiles of individual ligands. Taken together, our data extend the concept of functional selectivity to the H<sub>2</sub>R in human monocytes and demonstrate striking cell-type specificity in the pharmacological profile of the H<sub>2</sub>R.

© 2014 Elsevier Inc. All rights reserved.

## 1. Introduction

Monocytes are blood cells of the innate immune system. During infection, generation of cytokines or microbial products leads to migration of monocytes into peripheral tissue and subsequent differentiation into macrophages or dendritic cells (DCs) [1,2]. Moreover, monocytes are phagocytes and play a crucial role in the defense against microbial pathogens [3]. Upon exposure to specific stimuli,

monocytes release reactive oxygen species (ROS) produced by NADPH oxidase [4,5]. The bacterial peptide N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP) is a well-known stimulus for NADPH oxidase activation in monocytes [6,7]. Following binding to the G<sub>i</sub>-protein-coupled formyl peptide receptor (FPR) [8], fMLP activates phospholipase C (PLC), hydrolyzing phosphatidylinositol-4,5-bisphosphate (PIP<sub>2</sub>) into inositol-1,4,5-trisphosphate (IP<sub>3</sub>) and 1,2-diacylglycerol (DAG) [9]. DAG activates protein kinase C (PKC) [9] followed by NADPH oxidase activation [10].

Histamine (HA) inhibits fMLP-induced ROS release in myeloid cells via H<sub>2</sub>R [11,12] and is available as post-consolidation therapy for patients suffering from acute myeloid leukemia (AML) [13]. The mechanism of action of HA is assumed to involve activation of the H<sub>2</sub>R in myeloid cells. Targeting the H<sub>2</sub>R results in inhibition of ROS generation and prevents T-cells and natural killer (NK)-cells from undergoing apoptosis [14]. HA mediates its effects via four histamine receptor subtypes: H<sub>1</sub>R, H<sub>2</sub>R, H<sub>3</sub>R and H<sub>4</sub>R [15]. The H<sub>2</sub>R is expressed on human monocytes [16,17]. Canonically, the H<sub>2</sub>R couples to G<sub>s</sub>-proteins. Stimulation of G<sub>s</sub> leads to activation of adenylyl cyclases (ACs) and subsequent accumulation of adenosine-3',5'-cyclic monophosphate (cAMP) [18]. Additionally, in some cell systems the H<sub>2</sub>R couples non-canonically to G<sub>q</sub>-proteins resulting in PLC activation and increases in intracellular calcium concentration ([Ca<sup>2+</sup>]<sub>i</sub>) [19,20]. The H<sub>2</sub>R can also mediate non-canonical activation of ERK1/2 via β-arrestin [21].

The two-state model of GPCR activation describes two distinct receptor conformations where the receptor exists either in an

**Abbreviations:** AC, adenylyl cyclase; AM, amthamine; AML, acute myeloid leukemia; ATP, adenosine 5'-triphosphate; [Ca<sup>2+</sup>]<sub>i</sub>, intracellular calcium concentration; cAMP, adenosine-3',5'-cyclic monophosphate; DC, dendritic cell; DI, dimaprit; EPAC, exchange protein directly activated by cAMP; FAM, famotidine; fMLP, N-formyl-L-methionyl-L-leucyl-L-phenylalanine; FSK, forskolin; GPCR, G-protein-coupled receptor; HA, histamine; H<sub>2</sub>R, histamine H<sub>2</sub>-receptor; IBMX, 3-isobutyl-1-methylxanthine; IM, impromidine; JNJ, 1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine (JNJ7777120); MEP, mepyramine; PKA, protein kinase A; ROS, reactive oxygen species; Rp-cAMPS, adenosine-3',5'-cyclic monophosphorothioate, Rp-isomer; Rp-8-Br-cAMPS, 8-bromoadenosine-3',5'-cyclic monophosphorothioate, Rp-isomer; Sp-cAMPS, adenosine-3',5'-monophosphorothioate, Sp-isomer; Sp-cAMPS-AM, adenosine-3',5'-monophosphorothioate acetoxymethyl ester, Sp-isomer; Sp-8-Br-cAMPS-AM, 8-bromoadenosine-3',5'-cyclic monophosphorothioate acetoxymethyl ester, Sp-isomer; THIO, thioperamide; 5-MHA, 5-methylhistamine; 8-pCPT-2'-O-Me-cAMP, 8-(4-chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate.

\* Corresponding author. Tel.: +49 511 532 2805; fax: +49 511 532 4081.

E-mail addresses: [werner.kristin@mh-hannover.de](mailto:werner.kristin@mh-hannover.de) (K. Werner),

[Neumann.detlef@mh-hannover.de](mailto:Neumann.detlef@mh-hannover.de) (D. Neumann),

[seifert.roland@mh-hannover.de](mailto:seifert.roland@mh-hannover.de) (R. Seifert).

inactive (R) or active (R\*) state. Binding of agonists stabilize the R\* state facilitating GPCR activation [22,23]. This concept has been replaced by a more complex multiple-state model. In terms of the extended model, each ligand stabilizes a ligand-specific receptor conformation resulting in distinct activation of G-protein-dependent as well as G-protein-independent signaling pathways. This concept of ligand-specific GPCR conformations is also designated as functional selectivity or biased agonism [24,25].

The H<sub>2</sub>R in human monocytes has only been poorly studied so far. We already reported functional selectivity of the H<sub>2</sub>R in human eosinophils and neutrophils [11]. Our present study has three aims. First, we pharmacologically characterized the H<sub>2</sub>R in human monocytes with respect to cAMP accumulation and inhibition of fMLP-induced ROS generation. In this context, we studied functional selectivity in monocytes. Second, we analyzed the role of cAMP in the H<sub>2</sub>R-mediated inhibition of NADPH oxidase. Third, we investigated cell type-specific differences in pharmacology between eosinophils, neutrophils and monocytes.

## 2. Materials and methods

### 2.1. Materials

CD14 MicroBeads human, Pan Monocyte Isolation Kit human, autoMACS Pro Running Buffer and MACSQuant Running Buffer were purchased from Miltenyi Biotec (Bergisch-Gladbach, Germany). Impromidine (IM) was provided by Prof. Dr. A. Buschauer (Department of Pharmaceutical and Medicinal Chemistry II, University of Regensburg, Germany). Histamine dihydrochloride (HA), amthamine dihydrobromide (AM), dimaprit dihydrochloride (DI), 5-methylhistamine dihydrochloride (5-MHA), mepyramine maleate (MEP), JNJ7777120 (JNJ), thioperamide (THIO) and Fura-2AM were obtained from Tocris Bioscience (Bristol, UK). Propidium iodide, *N,N'*-dimethyl-9,9'-biacridinium dinitrat (lucigenin), *N*-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP), 3-isobutyl-1-methylxanthine (IBMX), adenosine 5'-triphosphate (ATP), forskolin (FSK) and famotidine (FAM) were supplied by Sigma-Aldrich (St. Louis, MO, USA). Stock solutions (10 mM) of IM, HA, AM, DI, 5-MHA, THIO, ATP, FAM and IBMX were prepared in distilled water and stock solutions (10 mM) of MEP, JNJ, FSK and fMLP in DMSO. Adenosine-3',5'-cyclic monophosphorothioate, Rp-isomer (Rp-cAMPS), 8-bromoadenosine-3',5'-cyclic monophosphorothioate, Rp-isomer (Rp-8-Br-cAMPS), 8-(4-chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclic monophosphate (8-pCPT-2'-O-Me-cAMP), adenosine-3',5'-monophosphorothioate, Sp-isomer (Sp-cAMPS), adenosine-3',5'-monophosphorothioate acetoxyethyl ester, Sp-isomer (Sp-cAMPS-AM) and 8-bromoadenosine-3',5'-cyclic monophosphorothioate acetoxyethyl ester, Sp-isomer (Sp-8-Br-cAMPS-AM) were obtained from BIOLOG (Bremen, Germany). Stock solutions (100 mM) of cAMP analogs were prepared in distilled water apart from Sp-cAMPS-AM and Sp-8-Br-cAMPS-AM which were dissolved in DMSO. H89 dihydrochloride and SQ 22536 were from Merck (Darmstadt, Germany). KT5720 was supplied by Enzo Life Sciences (Farmingdale, NY, USA). H89 and KT5720 were prepared as 10 mM stock solutions in DMSO. 10× Dulbecco's PBS without Ca<sup>2+</sup> and Mg<sup>2+</sup> was from PAA Laboratories (Pasching, Austria). Biocoll separation solution was purchased from Biochrom (Berlin, Germany). The FITC Mouse Anti-Human CD14 antibody was supplied by Becton Dickinson (Franklin Lakes, NJ, USA). Tenofovir was from the National Institutes of Health (Bethesda, MD, USA). RevertAid M-MuLV Reverse Transcriptase (200 U/μl), oligo(dT)<sub>18</sub> primer, random hexamer primer, dNTP mix (10 mM) and 5× Reaction Buffer were purchased from Fermentas (St. Leon-Rot, Germany). RiboLock RNase Inhibitor (40 U/μl) was supplied by Thermo Scientific (Wilmington, DE, USA). TaqMan probes

(Hs00939627\_m1 (GUSB) LOT#1191192, Hs00299832\_m1 (ADCY1) LOT#860374, Hs00392747\_m1 (ADCY2) LOT#866042, Hs00269618\_m1 (ADCY3) LOT#845604, Hs00328499\_m1 (ADCY4) LOT#910032, Hs00766287\_m1 (ADCY5) LOT#873551, Hs00209600\_m1 (ADCY6) LOT#845608, Hs00936808\_m1 (ADCY7) LOT#851741, Hs00181588\_m1 (ADCY8) LOT#817574, Hs00181599\_m1 (ADCY9) LOT#967631, Hs00218262\_m1 (ADCY10) LOT#964687) and TaqMan Gene Expression Master Mix were purchased from Applied Biosystems (Carlsbad, CA, USA).

### 2.2. Methods

#### 2.2.1. Isolation of human monocytes

The present study was approved by the Ethics Committee of the Hannover Medical School. For the isolation of human monocytes, venous blood of healthy human volunteers was drawn in EDTA blood collection tubes containing 1.6 mg EDTA/ml blood. Nine ml of blood were diluted with 10 ml of 1× phosphate buffered saline (Dulbecco's PBS without Ca<sup>2+</sup> and Mg<sup>2+</sup>). Subsequently, 15 ml of Biocoll separation solution (density: 1.077 g/ml) were slowly overlaid with the diluted blood and centrifuged at room temperature at 400 × g for 30 min without brake. The layer of peripheral blood mononuclear cells (PBMCs) was transferred into a new tube and 1× PBS was added to a final volume of 45 ml followed by a centrifugation at 300 × g for 10 min. The cell pellet was resuspended in 20 ml of 1× PBS and centrifuged at 200 × g for 10 min to remove thrombocytes. Afterwards, the cell number was determined using a Neubauer counting chamber.

PBMCs were incubated with CD14 MicroBeads or Pan Monocyte Isolation Kit following the manufacturer's instructions. Monocytes were isolated using the autoMACS Pro Separator (Miltenyi Biotec). Cell purity was assessed by CD14 staining and flow cytometry. For CD14 staining, monocytes (1 × 10<sup>4</sup> cells) were suspended in 100 μl of MACSQuant Running Buffer and 2 μl of FITC-conjugated CD14 antibody were added. Cells were incubated at 4 °C for 20 min and CD14-positive cells were detected using MACSQuant Analyzer (Miltenyi Biotec). For cell viability, 100 μg/ml propidium iodide was used. Purity and viability of monocytes were evaluated with the MACSQuantify Software (Miltenyi Biotec).

#### 2.2.2. Production of reactive oxygen species (ROS)

Measurement of ROS production in monocytes was performed via the lucigenin chemiluminescence assay [26,27]. The experiments were conducted in white 96-well plates to avoid disturbances of scattered light from adjacent wells. For this purpose, monocytes (1 × 10<sup>6</sup> cells/ml) were resuspended in Hank's Balanced Salt Solution (HBSS). 100 μl of cell suspension and 100 μl of 250 μM lucigenin were incubated in each well at 37 °C and 5% (v/v) CO<sub>2</sub> for 45 min. Subsequently, 50 μl of ligands at different concentrations were added to a volume of 250 μl. After pre-incubation at 37 °C for 5 min, reactions were started by addition of 25 μl of fMLP (1 μM final). To determine ROS production, chemiluminescence was recorded at 37 °C for 60 min by a Synergy 4 microplate reader (BioTek, Winooski, VT, USA). The chemiluminescence maxima between 10 and 30 min were used for data analysis.

#### 2.2.3. Quantification of cAMP levels

PBS, supplemented with 200 μM IBMX and 2 mM CaCl<sub>2</sub>, was pre-incubated with ligands at different concentrations to a total volume of 50 μl at 37 °C for 5 min. Monocytes (1 × 10<sup>7</sup> cells/ml) were resuspended in PBS and 50 μl of cell suspension were added to 2 ml safe-lock tubes followed by incubation at 37 °C for 10 min. In order to stop the reactions, tubes were placed on ice and subsequently heated at 95 °C for 10 min. After cooling down the samples on

Download English Version:

<https://daneshyari.com/en/article/2512151>

Download Persian Version:

<https://daneshyari.com/article/2512151>

[Daneshyari.com](https://daneshyari.com)